TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc. is trading at $65.99, down 1.68% on the session. The 50 day average sits at $81.65 and the 200 day at $94.48, which puts the stock in a downtrend. RSI is at 28.9, which reads as oversold, and MACD is bearish crossover. Volume is average.

The nearest support is around $64.64 with resistance near $89.80, so that band frames the current range. Average daily movement is roughly $3.64, or about 5.5% of the share price, which is what any stop placement has to allow for. The overall health score of 24 out of 100 combines a trend score of 3, momentum of 28 and a risk score of 50.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.